Low-grade serous ovarian cancer (LGSOC) is a rare ovarian malignancy primarily affecting younger women and is characterized by an indolent growth pattern. It exhibits indolent growth and high estrogen/progesterone receptor expression, suggesting potential responsiveness to endocrine therapy. However, treatment efficacy remains limited due to the development of endocrine resistance. The mechanisms of resistance, whether primary or acquired, are still largely unknown and present a significant hurdle in achieving favorable treatment outcomes with endocrine therapy in these patients. In estrogen receptor-positive breast cancer, mechanisms of endocrine resistance have been largely explored and novel treatment strategies to overcome resistance have emerged. Considering the shared estrogen receptor positivity in LGSOC and breast cancer, we wanted to explore whether there are any parallel mechanisms of resistance and whether we can extend endocrine breast cancer treatments to LGSOC. This review aims to highlight the underlying molecular mechanisms possibly driving endocrine resistance in ovarian cancer, while also exploring the available therapeutic opportunities to overcome this resistance. By unraveling the potential pathways involved and examining emerging strategies, this review explores valuable insights for advancing treatment options and improving patient outcomes in LGSOC, which has limited therapeutic options available.
低级别浆液性卵巢癌（LGSOC）是一种罕见的卵巢恶性肿瘤，主要影响年轻女性，其特征为惰性生长模式。该肿瘤生长缓慢且雌激素/孕激素受体高表达，提示其可能对内分泌治疗具有敏感性。然而，由于内分泌耐药性的产生，治疗效果仍然有限。无论是原发性还是获得性耐药，其机制在很大程度上仍不明确，这成为此类患者通过内分泌治疗获得良好疗效的主要障碍。在雌激素受体阳性乳腺癌中，内分泌耐药的机制已得到广泛研究，并且已出现克服耐药性的新型治疗策略。考虑到LGSOC与乳腺癌均具有雌激素受体阳性特征，我们旨在探讨两者是否存在相似的耐药机制，以及是否可将乳腺癌的内分泌治疗策略延伸应用于LGSOC。本综述旨在阐明可能导致卵巢癌内分泌耐药的潜在分子机制，同时探索当前可用于克服这种耐药性的治疗机会。通过揭示相关潜在通路并研究新兴策略，本综述为推进LGSOC治疗选择、改善患者预后提供了有价值的见解，而目前该疾病的治疗选择十分有限。
肿瘤(癌症)患者之家